| Jul 22 |
MIRA Posts More Positive Test Results
|
| Jul 18 |
MIRA Announces More Positive Test Results
|
| Jun 11 |
MIRA Announces Positive Test Results
|
| Jun 10 |
Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year
|
| May 29 |
Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance
|
| May 21 |
MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog
|
| May 20 |
Dow Falls Over 150 Points; Sohu Posts Q1 Loss
|
| May 20 |
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog
|
